vs
HARVARD BIOSCIENCE INC（HBIO）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
帕可Bio的季度营收约是HARVARD BIOSCIENCE INC的1.9倍（$44.6M vs $23.7M）。HARVARD BIOSCIENCE INC净利率更高（-12.0% vs -90.4%，领先78.4%）。帕可Bio同比增速更快（13.8% vs -3.3%）。HARVARD BIOSCIENCE INC自由现金流更多（$-545.0K vs $-19.9M）。过去两年帕可Bio的营收复合增速更高（7.3% vs -1.6%）
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
HBIO vs PACB — 直观对比
营收规模更大
PACB
是对方的1.9倍
$23.7M
营收增速更快
PACB
高出17.2%
-3.3%
净利率更高
HBIO
高出78.4%
-90.4%
自由现金流更多
HBIO
多$19.4M
$-19.9M
两年增速更快
PACB
近两年复合增速
-1.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $23.7M | $44.6M |
| 净利润 | $-2.8M | $-40.4M |
| 毛利率 | 59.7% | 37.1% |
| 营业利润率 | 7.2% | -92.3% |
| 净利率 | -12.0% | -90.4% |
| 营收同比 | -3.3% | 13.8% |
| 净利润同比 | -15916.7% | -1802.7% |
| 每股收益（稀释后） | $-0.06 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HBIOPACB
| Q4 25 | $23.7M | $44.6M | ||
| Q3 25 | $20.6M | $38.4M | ||
| Q2 25 | $20.4M | $39.8M | ||
| Q1 25 | $21.8M | $37.2M | ||
| Q4 24 | $24.6M | $39.2M | ||
| Q3 24 | $22.0M | $40.0M | ||
| Q2 24 | $23.1M | $36.0M | ||
| Q1 24 | $24.5M | $38.8M |
净利润HBIOPACB
| Q4 25 | $-2.8M | $-40.4M | ||
| Q3 25 | $-1.2M | $-38.0M | ||
| Q2 25 | $-2.3M | $-41.9M | ||
| Q1 25 | $-50.3M | $-426.1M | ||
| Q4 24 | $18.0K | $2.4M | ||
| Q3 24 | $-4.8M | $-60.7M | ||
| Q2 24 | $-2.9M | $-173.3M | ||
| Q1 24 | $-4.7M | $-78.2M |
毛利率HBIOPACB
| Q4 25 | 59.7% | 37.1% | ||
| Q3 25 | 58.4% | 41.4% | ||
| Q2 25 | 56.4% | 36.9% | ||
| Q1 25 | 56.0% | -3.7% | ||
| Q4 24 | 57.1% | 25.6% | ||
| Q3 24 | 58.1% | 25.0% | ||
| Q2 24 | 57.2% | 16.5% | ||
| Q1 24 | 60.3% | 29.1% |
营业利润率HBIOPACB
| Q4 25 | 7.2% | -92.3% | ||
| Q3 25 | 1.0% | -101.1% | ||
| Q2 25 | -4.0% | -112.8% | ||
| Q1 25 | -228.1% | -1154.5% | ||
| Q4 24 | 0.0% | -390.1% | ||
| Q3 24 | -8.5% | -160.3% | ||
| Q2 24 | -9.0% | -488.3% | ||
| Q1 24 | -9.3% | -209.6% |
净利率HBIOPACB
| Q4 25 | -12.0% | -90.4% | ||
| Q3 25 | -6.0% | -98.9% | ||
| Q2 25 | -11.2% | -105.4% | ||
| Q1 25 | -231.2% | -1146.8% | ||
| Q4 24 | 0.1% | 6.0% | ||
| Q3 24 | -21.9% | -151.9% | ||
| Q2 24 | -12.7% | -481.3% | ||
| Q1 24 | -19.1% | -201.4% |
每股收益（稀释后）HBIOPACB
| Q4 25 | $-0.06 | $-0.11 | ||
| Q3 25 | $-0.03 | $-0.13 | ||
| Q2 25 | $-0.05 | $-0.14 | ||
| Q1 25 | $-1.14 | $-1.44 | ||
| Q4 24 | $0.01 | $-0.44 | ||
| Q3 24 | $-0.11 | $-0.22 | ||
| Q2 24 | $-0.07 | $-0.64 | ||
| Q1 24 | $-0.11 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.6M | $279.5M |
| 总债务越低越好 | $35.9M | — |
| 股东权益账面价值 | $13.7M | $5.3M |
| 总资产 | $80.1M | $784.1M |
| 负债/权益比越低杠杆越低 | 2.61× | — |
8季度趋势，按日历期对齐
现金及短期投资HBIOPACB
| Q4 25 | $8.6M | $279.5M | ||
| Q3 25 | $6.8M | $298.7M | ||
| Q2 25 | $7.4M | $314.7M | ||
| Q1 25 | $5.5M | $343.1M | ||
| Q4 24 | $4.1M | $389.9M | ||
| Q3 24 | $4.6M | $471.1M | ||
| Q2 24 | $4.0M | $509.8M | ||
| Q1 24 | $4.3M | $561.9M |
总债务HBIOPACB
| Q4 25 | $35.9M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $34.9M | — | ||
| Q1 25 | $36.4M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $34.9M | — | ||
| Q2 24 | $35.7M | — | ||
| Q1 24 | $35.6M | — |
股东权益HBIOPACB
| Q4 25 | $13.7M | $5.3M | ||
| Q3 25 | $14.1M | $36.1M | ||
| Q2 25 | $15.7M | $61.5M | ||
| Q1 25 | $14.8M | $91.6M | ||
| Q4 24 | $63.3M | $506.6M | ||
| Q3 24 | $65.3M | $453.1M | ||
| Q2 24 | $67.2M | $492.7M | ||
| Q1 24 | $68.8M | $649.0M |
总资产HBIOPACB
| Q4 25 | $80.1M | $784.1M | ||
| Q3 25 | $78.0M | $803.2M | ||
| Q2 25 | $80.1M | $825.5M | ||
| Q1 25 | $79.8M | $860.8M | ||
| Q4 24 | $126.6M | $1.3B | ||
| Q3 24 | $131.2M | $1.5B | ||
| Q2 24 | $128.9M | $1.5B | ||
| Q1 24 | $133.2M | $1.7B |
负债/权益比HBIOPACB
| Q4 25 | 2.61× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.22× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-96.0K | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $-545.0K | $-19.9M |
| 自由现金流率自由现金流/营收 | -2.3% | -44.6% |
| 资本支出强度资本支出/营收 | 1.9% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.5M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流HBIOPACB
| Q4 25 | $-96.0K | $-19.1M | ||
| Q3 25 | $1.1M | $-18.7M | ||
| Q2 25 | $2.8M | $-29.4M | ||
| Q1 25 | $3.0M | $-44.1M | ||
| Q4 24 | $1.7M | $-30.6M | ||
| Q3 24 | $-842.0K | $-45.5M | ||
| Q2 24 | $-846.0K | $-54.3M | ||
| Q1 24 | $1.4M | $-75.7M |
自由现金流HBIOPACB
| Q4 25 | $-545.0K | $-19.9M | ||
| Q3 25 | $877.0K | $-18.8M | ||
| Q2 25 | $2.7M | $-29.9M | ||
| Q1 25 | $2.5M | $-45.4M | ||
| Q4 24 | $1.4M | $-32.3M | ||
| Q3 24 | $-1.7M | $-46.3M | ||
| Q2 24 | $-1.7M | $-55.7M | ||
| Q1 24 | $758.0K | $-79.6M |
自由现金流率HBIOPACB
| Q4 25 | -2.3% | -44.6% | ||
| Q3 25 | 4.3% | -48.9% | ||
| Q2 25 | 13.0% | -75.3% | ||
| Q1 25 | 11.4% | -122.3% | ||
| Q4 24 | 5.8% | -82.3% | ||
| Q3 24 | -7.8% | -115.7% | ||
| Q2 24 | -7.2% | -154.8% | ||
| Q1 24 | 3.1% | -205.0% |
资本支出强度HBIOPACB
| Q4 25 | 1.9% | 1.9% | ||
| Q3 25 | 1.0% | 0.2% | ||
| Q2 25 | 0.4% | 1.4% | ||
| Q1 25 | 2.4% | 3.7% | ||
| Q4 24 | 1.2% | 4.1% | ||
| Q3 24 | 4.0% | 2.0% | ||
| Q2 24 | 3.5% | 4.1% | ||
| Q1 24 | 2.6% | 10.0% |
现金转化率HBIOPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 95.83× | -12.93× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
